Infertility is a pressing global health issue, impacting millions of people of reproductive age around the world, according to the World Health Organization (WHO). Recent data reveals that infertility affects a staggering 48 million couples and 186 million individuals globally. Infertility can arise from various factors, including male, female, or combined factors, and sometimes remains unexplained. Environmental and lifestyle factors such as smoking, excessive alcohol consumption, obesity, and exposure to pollutants are known to contribute to lower fertility rates, further emphasizing the urgency of effective infertility treatments.

The Role of Fertility Medications

Fertility medications are a standard component of infertility treatments, including in-vitro fertilization (IVF), and are employed to prepare the body for treatment, enhancing the chances of releasing healthy eggs from the ovaries. Decreasing fertility rates, a surge in the number of fertility clinics worldwide, technological advancements, and increased public-private partnerships, funding, and grants are driving advancements in infertility treatments, thus shaping the infertility drugs market.

Lifestyle Disorders on the Rise

The prevalence of lifestyle disorders is a significant driver of market growth. Poor diet and lifestyle issues such as stress, smoking, obesity, diabetes, and polycystic ovarian syndrome (PCOS) are becoming more common, elevating the demand for infertility medications. Stress, particularly related to job security, has been linked to delayed pregnancy, with women and men experiencing daily stress levels showing lower odds of conceiving. Stress-related hormones can impact fertility in both genders. In 2020, approximately 190 million people reported higher stress levels than in previous years, potentially affecting fertility and driving the demand for infertility drugs.

The Impact of Lifestyle Disorders on Diabetes

Lifestyle disorders, notably diabetes, contribute to the rising infertility rates. Factors like obesity, age, ethnicity, lifestyle, socioeconomic status, education, and urbanization are driving the increased prevalence of diabetes, which has been associated with lower fertility and reproductive health in both men and women. Diabetes can affect hormones, leading to delayed or unsuccessful implantation and fertilization. In the United States, approximately 35% of the under-20 population is expected to be affected by diabetes, further underscoring the growing need for infertility drugs.

Demand for Female Infertility Treatment

In the forecast period, the female infertility treatment segment is expected to dominate the infertility drugs market by patient type. Factors such as declining female fertility rates, the availability of various treatment options, and the expansion of fertility facilities worldwide are propelling the growth of this segment. Thyroid-related disorders and breast cancer are becoming increasingly prevalent among women, leading to a notable decline in fertility rates. Additionally, factors like increased smoking, alcohol consumption, and the prevalence of conditions such as PCOS and uterine fibroids are contributing to the rising demand for female infertility treatment.

Global Outlook: North America Leading, Asia Pacific Expanding

North America is poised to take the lead in the global infertility medications market during the forecast period. The regions dominance is attributed to the rising incidence of menopausal conditions, urinary infections, thyroid disorders, endometriosis, and other health issues resulting from busy lifestyles and elevated stress levels. The presence of a higher number of reproductive endocrinologists, robust healthcare infrastructure, and government initiatives in womens healthcare awareness are further fueling the expansion of the infertility drugs market in the United States.

Asia Pacific is also a significant player in the infertility drugs market. The region is experiencing a surge in medical tourism, growing awareness about infertility treatment options, an increasing number of fertility centers, rising healthcare expenditures, and government initiatives to improve infertility treatment accessibility in emerging nations. India, in particular, has witnessed substantial growth in fertility centers, driven by surrogacy and egg/sperm donation knowledge. The trend of delayed first-time motherhood due to career priorities and the prevalence of gynecological diseases among women further contribute to the growth of the Asia Pacific infertility drugs market.

Competitive Landscape

Market players are introducing new products and forming strategic alliances and partnerships. For instance, CooperSurgical recently entered into a multi-year strategic partnership with Virtus Health to drive innovation and digitization in fertility treatment. Hamilton Thorne Ltd. received FDA approval for the sale of GYNEMED GM501, a device designed for in vitro washing and handling of oocytes and human embryos.

Key players in the infertility drugs market include Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A., and Thermax.

Global Industry Analysis (2018 2021) Growth Trends and Market Forecast (2022 2027)

Our Blogs:

About Us

Fairfield Market Research is a UK-based market research provider. Fairfield offers a wide spectrum of

services, ranging from customized reports to consulting solutions. With a strong European footprint, Fairfield operates globally and helps businesses navigate through business cycles, with quick responses and multi-pronged approaches. The company values an eye for insightful take on global matters, ably backed by a team of exceptionally experienced researchers. With a strong repository of syndicated market research reports that are continuously published & updated to ensure the ever-changing needs of customers are met with absolute promptness.


Fairfield Market Research

London, UK

UK +44 (0)20 30025888

USA (Toll-free) +1 (844) 3829746



LinkedIn | Twitter

This press release first seen on Brilad

comtex tracking